Statement: FDA Must Reject Tanezumab as a Treatment for Osteoarthritis Due to Unacceptable Dangers, Little to No Benefit
CAFTA Deals Watchdog Report: In Exchange for Supporting CAFTA, Will Rep. Sanford Bishop Buy the Same Peanut of a Deal He Was Promised (and Betrayed on) in 1997? July 26, 2005